3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Lymphoma, Follicular
3
Lymphoma
3
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Zollinger-Ellison Syndrome
1
Uterine Cervical Neoplasms
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphomatoid Granulomatosis
1
Kidney Neoplasms
1
Gastrointestinal Cancer Metastatic
1
Epstein-Barr Virus Infections
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Blast Crisis
1
Adenoma, Islet Cell
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
Interferons
×
Clear all
NCT00276536
2015-10-14
IFNa
The Cleveland Clinic
Phase 1
Completed
35 enrolled